WuXi Biologics (Cayman) Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €4.58B +10.9% €1.06B +16.8% 23.2% +0.012 pp N/A N/A
    (estimated) €4.13B +19.4% €909.74M +24.7% 22.0% +0.0093 pp €838.98M +54.6% 20.3% +0.046 pp
    (estimated) €3.45B +15.2% €729.70M +17.7% 21.1% +0.0044 pp €542.73M +89.1% 15.7% +0.061 pp
    (estimated) €3.00B +15.9% €620.02M +13.9% 20.7% -0.0036 pp €286.96M +118.4% 9.6% +0.045 pp
    (estimated) €2.59B +14.5% €544.52M +34.1% 21.0% +0.031 pp €131.40M -88.1% 5.1% -0.44 pp
    €2.26B +9.6% €406.18M -1.3% 18.0% -0.020 pp €1.11B +2.8% 49.0% -0.033 pp
    €2.06B +11.6% €411.46M -23.1% 20.0% -0.090 pp €1.08B -22.0% 52.2% -0.22 pp
    €1.85B +48.4% €534.98M +30.5% 29.0% -0.040 pp €1.38B +14.8% 74.7% -0.22 pp
    €1.25B +83.3% €410.10M +100.6% 32.9% +0.028 pp €1.20B +25.7% 96.6% -0.44 pp
    €679.25M +40.9% €204.40M +66.6% 30.1% +0.046 pp €956.85M +78.9% 140.9% +0.30 pp
    €482.13M +57.2% €122.70M +60.8% 25.4% +0.0057 pp €534.78M +110.2% 110.9% +0.28 pp
    €306.74M +56.6% €76.32M +149.6% 24.9% +0.093 pp €254.42M +103.9% 82.9% +0.19 pp
    €195.92M +63.7% €30.57M +79.0% 15.6% +0.013 pp €124.76M +101.8% 63.7% +0.12 pp
    €119.70M +77.6% €17.08M +217.0% 14.3% +0.063 pp €61.82M +15.7% 51.6% -0.28 pp
    €67.42M +67.9% €5.39M +6.0% 8.0% -0.047 pp €53.43M +508.6% 79.3% +0.57 pp
    €40.16M €5.08M 12.6% €8.78M 21.9%

    Notifications